$Celularity(CELU.US)$ NEWS Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy Celularity (NASDAQ: CELU) has announced that data published in the Journal for ImmunoTherapy of Cancer highlights the benefits of its placental-derived T-Cell platform for CAR-T therapies. The study revealed that CAR-T cells from Celularity's platform demonstrated greater persistence, resistance to exhaustion, and efficacy compared to tho...
$Celularity(CELU.US)$Celularity To Present Data Showing Senescent Cell Elimination By Off-The-Shelf Natural Killer Cells Derived From Human Placental Cells Benzinga· 2 mins ago
$Celularity(CELU.US)$Celularity Receives Healthcare Common Procedure Coding System Q Code Approval From The U.S. Centers For Medicare & Medicaid Services For Biovance 3L Benzinga· 1 min ago
$Celularity(CELU.US)$Celularity Submits Request To US FDA For Orphan Drug Designation For PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
Celularity's low P/S ratio may be due to declining revenue, not keeping pace with the industry. Despite a recent share price jump, it's not in line with industry median. If medium-term revenue trends persist, significant share price movement seems unlikely.
Jaguar8 : 我很喜歡!
Trytosaveabit樓主 Jaguar8: 如果它是美國專利,它將獲得更多的關注!嘿河